Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. John A. Boockvar

Neurosurgery
North Shore-Lij Medical PC
330 Community Dr, 
Manhasset, NY 
Offers Telehealth
Distinguished in Primitive Neuroectodermal Tumor (PNET)
North Shore-Lij Medical PC
330 Community Dr, 
Manhasset, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Boockvar is a Neurosurgery provider in Manhasset, New York. Dr. Boockvar is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Laminectomy.

His clinical research consists of co-authoring 173 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in NY
Hospital Affiliations
Lenox Hill Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
View 6 Less Insurance Carriers -

Locations

NORTH SHORE-LIJ MEDICAL PC
330 Community Dr, Manhasset, NY 11030
Other Locations
NORTH SHORE-LIJ MEDICAL PC
130 E 77th St, New York, NY 10075
NORTH SHORE-LIJ MEDICAL PC
300 Community Dr, Manhasset, NY 11030
NORTH SHORE-LIJ MEDICAL PC
350 Community Dr, Manhasset, NY 11030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: EGFR(V)-EDV-Dox
Study Phase: Phase 1
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Enrollment Status: Suspended
Publish Date: April 09, 2025
Intervention Type: Procedure
Study Phase: Phase 1
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Glioblastoma Multiforme (GBM)
Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Glioblastoma Multiforme (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug
Study Drug: Bevacizumab
Study Phase: Phase 1/Phase 2
Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
Enrollment Status: Terminated
Publish Date: November 03, 2021
Intervention Type: Drug
Study Drug: Intra-arterial Cerebral Infusion of Trastuzumab
Study Phase: Phase 1
Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Terminated
Publish Date: November 03, 2021
Intervention Type: Drug
Study Drug: Cetuximab
Study Phase: Phase 1
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults
A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: December 11, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 11 Less Clinical Trials

173 Total Publications

Safety and efficacy of selective and superselective intra-arterial cerebral infusion with blood-brain barrier disruption for glioma: a systematic review and meta-analysis.
Safety and efficacy of selective and superselective intra-arterial cerebral infusion with blood-brain barrier disruption for glioma: a systematic review and meta-analysis.
Journal: Journal of neurointerventional surgery
Published: July 23, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Douglas S. Kondziolka
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Douglas S. Kondziolka
Neurosurgery

New York University

111 Broadway, Fl 2, 
New York, NY 
 (16.9 miles away)
212-263-9701
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Kondziolka is a Neurosurgery provider in New York, New York. Dr. Kondziolka is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Schwannoma, Acoustic Neuroma, Arteriovenous Malformation, Gamma Knife Radiosurgery, and Rhizotomy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lee E. Tessler
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lee E. Tessler
Neurosurgery

New York University

200 Old Country Rd, Suite 485, 
Mineola, NY 
 (4.0 miles away)
516-663-4822
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lee Tessler is a Neurosurgery provider in Mineola, New York. Dr. Tessler is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Radiation Induced Meningioma, Meningioma, Posterior Fossa Tumor, Awake Craniotomy, and Gamma Knife Radiosurgery.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
 (13.3 miles away)
212-241-4572
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boockvar's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 10 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile